Suzuki, Ritsuro
Shimane University,
Japan
2025 Rank: 93064
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1706 out of 166615 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 93064 | 102415 |
| Total Cites | 877 | 974 |
| H-index | 14 | 14 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 17 | 17 |
| Total Cites to Single Authored Papers | 12 | 12 |
| Number of Single+First Authored Papers | 37 | 37 |
| Total Cites to Single+First Authored Papers | 58 | 58 |
| Number of Single+First+Last Authored Papers | 75 | 75 |
| Total Cites to Single+First+Last Authored Papers | 158 | 163 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 670 | 736 |
| Ratio of Total Citations to Distinct Citing Papers | 1.31 | 1.32 |
| Self-Citation Percentage |
9.96%
|
|
Suzuki, Ritsuro
Shimane University Faculty of Medicine,
Japan
2024 Rank: 160250
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 3013 out of 157372 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 160250 | 164294 |
| Total Cites | 858 | 956 |
| H-index | 13 | 14 |
| Hm-index | 3 | 4 |
| Number of Single Authored Papers | 16 | 16 |
| Total Cites to Single Authored Papers | 3 | 3 |
| Number of Single+First Authored Papers | 36 | 36 |
| Total Cites to Single+First Authored Papers | 39 | 40 |
| Number of Single+First+Last Authored Papers | 73 | 73 |
| Total Cites to Single+First+Last Authored Papers | 141 | 148 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 671 | 729 |
| Ratio of Total Citations to Distinct Citing Papers | 1.28 | 1.31 |
| Self-Citation Percentage |
10.25%
|
|
Suzuki, Ritsuro
Shimane University Hospital,
Japan
2023 Rank: 108796
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 2284 out of 147556 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 108796 | 104445 |
| Total Cites | 901 | 1064 |
| H-index | 13 | 15 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 16 | 16 |
| Total Cites to Single Authored Papers | 10 | 10 |
| Number of Single+First Authored Papers | 36 | 36 |
| Total Cites to Single+First Authored Papers | 45 | 45 |
| Number of Single+First+Last Authored Papers | 71 | 71 |
| Total Cites to Single+First+Last Authored Papers | 144 | 156 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 697 | 788 |
| Ratio of Total Citations to Distinct Citing Papers | 1.29 | 1.35 |
| Self-Citation Percentage |
15.32%
|
|
Suzuki, Ritsuro
Shimane University Hospital,
Japan
2022 Rank: 69241
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1683 out of 138599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 69241 | 63079 |
| Total Cites | 937 | 1151 |
| H-index | 13 | 15 |
| Hm-index | 4 | 5 |
| Number of Single Authored Papers | 16 | 16 |
| Total Cites to Single Authored Papers | 16 | 16 |
| Number of Single+First Authored Papers | 36 | 36 |
| Total Cites to Single+First Authored Papers | 66 | 71 |
| Number of Single+First+Last Authored Papers | 69 | 69 |
| Total Cites to Single+First+Last Authored Papers | 166 | 191 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 727 | 835 |
| Ratio of Total Citations to Distinct Citing Papers | 1.29 | 1.38 |
| Self-Citation Percentage |
18.59%
|
|
Suzuki, Ritsuro
Shimane University Hospital,
Japan
2021 Rank: 62559
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1423 out of 127911 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 62559 | 60331 |
| Total Cites | 1398 | 1733 |
| H-index | 18 | 19 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 16 | 16 |
| Total Cites to Single Authored Papers | 26 | 26 |
| Number of Single+First Authored Papers | 36 | 36 |
| Total Cites to Single+First Authored Papers | 108 | 111 |
| Number of Single+First+Last Authored Papers | 62 | 62 |
| Total Cites to Single+First+Last Authored Papers | 253 | 288 |
| Composite Score | 2 | 3 |
| Number of Distinct Citing Papers | 1099 | 1294 |
| Ratio of Total Citations to Distinct Citing Papers | 1.27 | 1.34 |
| Self-Citation Percentage |
19.33%
|
|
Suzuki, Ritsuro
Shimane University,
Japan
2020 Rank: 52394
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1128 out of 108509 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 52394 | 49418 |
| Total Cites | 1119 | 1431 |
| H-index | 17 | 19 |
| Hm-index | 5 | 6 |
| Number of Single Authored Papers | 16 | 16 |
| Total Cites to Single Authored Papers | 19 | 20 |
| Number of Single+First Authored Papers | 36 | 36 |
| Total Cites to Single+First Authored Papers | 90 | 96 |
| Number of Single+First+Last Authored Papers | 62 | 62 |
| Total Cites to Single+First+Last Authored Papers | 169 | 196 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 892 | 1072 |
| Ratio of Total Citations to Distinct Citing Papers | 1.25 | 1.33 |
| Self-Citation Percentage |
21.80%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.